WS

West Pharmaceutical Services, Inc.

WSTHealthcareNASDAQ

Medical Instruments & Supplies

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$3.07B
+6.3% YoY
Net Income
$493.7M
+0.2% YoY
EBITDA
$772.8M
+3.9% YoY
Free Cash Flow
$275.7M

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11CONFIRMED RSI OverboughtRSI 72.3, above 70, stock may be overbought
MACD Negative CrossoverHistogram -0.4954, negative momentum
Jul 10 RSI OverboughtRSI 79.3, above 70, stock may be overbought
About West Pharmaceutical Services, Inc.

Headquartered within the healthcare sector, West Pharmaceutical Services, Inc. focuses on Medical Instruments & Supplies services and products. West Pharmaceutical Services, Inc. At a $25.31B market cap, West Pharmaceutical Services, Inc. ranks as a large-cap company within healthcare. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Key stats
Market Cap$25.31B
P/E (TTM)47.96
Fwd P/E37.24
EPS$7.47
Beta1.16
52W Change+69.9%
Dividend Yield0.24%
ROE19.1%
Analysis

West Pharmaceutical Services, Inc. holds $521.4M in cash against $321.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $275.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 19.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.2% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $2.89B (2022) to $3.07B (2025).

As with any equity investment, WST carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing WST.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms